Amedisys (AMED)
(Delayed Data from NSDQ)
$96.12 USD
+0.08 (0.08%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $96.15 +0.03 (0.03%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$96.12 USD
+0.08 (0.08%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $96.15 +0.03 (0.03%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth D Momentum B VGM
Zacks News
Republicans Take Last Shot at Obamacare: 5 MedTech Stocks to Buy
by Zacks Equity Research
The fate of Obamacare will be decided on Sep. 30. No matter what the future holds, the day will provide investors a clear picture of where the MedTech industry is headed.
Boston Scientific MultiSENSE Study on HeartLogic Positive
by Zacks Equity Research
Boston Scientific (BSX) positive clinical trial data on HeartLogic should boost the Rhythm Management segment.
Becton, Dickinson Ultra-Fine Needle to Improve Diabetic Care
by Zacks Equity Research
Becton, Dickinson and Company's (BDX) latest micro pen needle will enhance the scope of its Diabetic Care unit.
Neogen (NEOG) Earnings and Revenues Beat Estimates in Q1
by Zacks Equity Research
Neogen (NEOG) rides high on balanced growth across all business segments.
Varian Medical (VAR) Releases FDA-Approved Eclipse 15.5
by Zacks Equity Research
Varian Medical (VAR) is consistently trying to turn around its Oncology Systems business.
Will Hurricanes Choke Cardiovascular (CSII) Q1 Performance?
by Zacks Equity Research
Cardiovascular (CSII) expects Q1 revenues to be affected by the Harvey and Irma hurricanes. However, the long-term growth prospects are unlikely to be affected.
5 MedTech Stocks to Pick for Stellar Returns
by Zacks Equity Research
While the MedTech industry has been grappling with multiple issues, these stocks with high growth potential can be great bets.
Why the Earnings Streak Will Continue for Amedisys (AMED)
by Zacks Equity Research
Amedisys (AMED) can be a harbinger of out performance and a signal for a strong earnings profile on the back of its favorable Zacks rank and earnings ESP in the positive territory.
Inovalon Holdings' ONE Platform Chosen by UnitedHealthcare
by Zacks Equity Research
Inovalon Holding (INOV) will be able to expand in the population health management space through the selection of its proprietary ONE Platform by UnitedHealthcare.
Fresenius Medical Opens Manufacturing Plant in Malaysia
by Zacks Equity Research
Fresenius Medical's (FMS) Malaysian plant will strengthen the company's presence in the rapidly-growing market.
Amedisys Rides High on Strong Prospects Amid Margin Woes
by Zacks Equity Research
Strength in Hospice and Personal Care businesses are offsetting the weakness in Amedisys' (AMED) Home Health Medicare business.
Medtronic's IN.PACT Admiral Approval in Japan Boosts APV Arm
by Zacks Equity Research
Medtronic's (MDT) receipt of Japanese regulatory approval for IN.PACT Admiral Drug-Coated Balloon (DCB) is expected to boost the top line.
IDEXX Laboratories Rides High on Strong CAG, Global Growth
by Zacks Equity Research
IDEXX (IDXX) rides high on balanced segmental growth with significant contributions from the Companion Animal Group business. Moreover, strong fundamentals buoy optimism.
Medtronic Launches StealthStation Technology, Expands in ENT
by Zacks Equity Research
Medtronic (MDT) recently launched StealthStation ENT, which enables surgeons to gain better visualization.
Centene's Fidelis Care Buyout to Expand Presence in New York
by Zacks Equity Research
Centene's (CNC) acquisition of Fidelis Care for $3.75 billion for expanding in New York, is expected to impact Centene's top line and bottom line positively.
5 Discounted MedTech Stocks for a Healthy Portfolio
by Zacks Equity Research
In view of the current political scenario and banking on favorable metrics, these five MedTech stocks stand out as the most suitable value picks.
Universal Health (UHS) Grows on Buyouts, Expenses a Drag
by Zacks Equity Research
Despite solid revenue growth backed by inorganic strategies, Universal Health's (UHS) rising level of debt and expenses continue to weigh on margins.
Top Ranked Growth Stocks to Buy for September 11th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, September 11th:
Amedisys to Buy Intercity Home Care, Boosts Personal Care Arm
by Zacks Equity Research
Amedisys (AMED) to strengthen its position in Personal Care business in Massachusetts with this recently signed acquisition deal.
3 Excellent Value Picks as Political Chaos Grips MedTech
by Zacks Equity Research
In view of the current political scenario and banking on favorable metrics, these three MedTech stocks stand out as the most suitable value picks.
Ensign Group's Inorganic Growth Impresses, Debt Level Hurts
by Zacks Equity Research
Ensign Group's (ENSG) top line rises on inorganic and organic growth. Its financial health also impresses. However high level of costs and debts bother.
Molina Healthcare's Top Line Grows on Membership, Debts Hurt
by Zacks Equity Research
Molina Healthcare's (MOH) top line benefits from inorganic growth and membership. However, rising level of debt and expenses hurt margins.
WellCare Health Partners Mission Health to Improve Offerings
by Zacks Equity Research
WellCare Health Plans, Inc's (WCG) subsidiary, Wellcare of North Carolina recently entered into an agreement with Mission Health to provide better Medicaid and Medicare services in North Carolina.
Centene (CNC) Poised to Grow on Buyouts, High Debt Bothers
by Zacks Equity Research
Centene's (CNC) accretive acquisitions backed by solid financials add to its top line. However, high debt and rising expenses hurt margins.
Amedisys (AMED) Up 3.6% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Amedisys (AMED) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.